20-Hydroxyecdysone
CAS 5289-74-7
20-Hydroxyecdysone (CAS 5289-74-7) is a Phase 2 pharmaceutical compound with 5 bioactivity targets and 0 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | IC50 | 7153.968181818182 nM | 10 | - |
| - | Potency | 158467.9 nM | 5 | - |
| - | MIC | 109.25 ug.mL-1 | 4 | - |
| - | Ki | 2750 nM | 2 | - |
| - | EC50 | 53550 nM | 1 | - |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is 20-Hydroxyecdysone used for in pharmaceutical contexts?
20-Hydroxyecdysone (CAS 5289-74-7) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for 20-Hydroxyecdysone?
No adverse-event association or SIDER side-effect rows are rendered for 20-Hydroxyecdysone in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is 20-Hydroxyecdysone also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Cyanotis Arachnoidea Root Extract with EU status "permitted".
What clinical phase is 20-Hydroxyecdysone in?
20-Hydroxyecdysone is rendered with ChEMBL max phase 2.